[The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats]

Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 Jul;42(4):471-4.
[Article in Chinese]

Abstract

Objective: To investigate the therapeutic effect of PI3Kgamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by Isoproterenol in rats.

Methods: Wistar rats were randomly divided into three groups (n = 10), control group, ISO group (vehicle group) and AS605240 group. The rats in control group without any treatment. The rats in ISO and AS605240 group were given ISO 10 mg/kg for 3 days and 5 mg/kg for another 11 days by subcutaneous injection to prepare the animal model of cardiac fibrosis. Rats in AS605240 group were given AS605240 50 mg/(kg x d) by intraperitoneal injection continuously for 14 days. The vehicle group received the intraperitoneal injection of an equal volume of 0.5% carboxymethylcellulose. Twenty-four hours after the last treatment, rats were sacrificed. Heart, body weight, cardiac function and the CVF were measured.

Results: Compared with the control group, the HW/BW of ISO group was increased significantly (P < 0.05) with a increased collagen inter cardiac muscle cells (P < 0. 05). Compared with ISO group, histological examination of the heart showed that AS605240 significantly relieved the rat cardiac fibrosis and reduced heart/body weight ratios in experimental cardiac fibrosis (P < 0.05).

Conclusion: AS605240 may be an effective antagonist for cardiac hypertrophy and cardiac fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiomegaly / chemically induced
  • Cardiomegaly / drug therapy*
  • Fibrosis / chemically induced
  • Fibrosis / drug therapy
  • Isoproterenol / pharmacology*
  • Male
  • Myocardium / pathology*
  • Proteasome Endopeptidase Complex
  • Proteins / antagonists & inhibitors*
  • Quinoxalines / pharmacology*
  • Quinoxalines / therapeutic use
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Thiazolidinediones / pharmacology*
  • Thiazolidinediones / therapeutic use

Substances

  • 5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione
  • PSMF1 protein, human
  • Proteins
  • Quinoxalines
  • Thiazolidinediones
  • Proteasome Endopeptidase Complex
  • Isoproterenol